List of insiders holdings for Day One Biopharmaceuticals Inc.:
- Shares directly owned by the insider.
- Shares indirectly owned by the insider.
- Total shares owned by the insider (sum of shares directly and indirectly owned).
- Total market value if available.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| # | Insider Holder Name | Report Date Time |
Shares Owned Directly Indirectly |
Total Shares Owned |
Filing |
| 1 | AI Day1 LLC Access Industries Holdings LLC ACCESS INDUSTRIES MANAGEMENT LLC Blavatnik Len 10% Owner |
2024-08-05 17:05:27 | 12,929,322 0 |
12,929,322 | Form 13D |
| 2 | Atlas Venture Opportunity Fund II L.P. Atlas Venture Fund XI L.P. Atlas Venture Associates XI L.P. Atlas Venture Associates XI LLC Atlas Venture Opportunity Fund I L.P. Atlas Venture Associates Opportunity I L.P. Atlas Venture Associates Opportunity I LLC 10% Owner |
2024-11-14 16:30:11 | 4,869,681 0 |
4,869,681 | Form 13G |
| 3 | Atlas Venture Fund XI L.P. 10% Owner |
2024-11-14 16:30:11 | 4,869,681 0 |
4,869,681 | Form 13G |
| 4 | Atlas Venture Fund XI L.P. Atlas Venture Opportunity Fund I L.P. ATLAS VENTURE ASSOCIATES X L.P. Atlas Venture Associates X LLC Atlas Venture Associates Opportunity I LLC Atlas Venture Associates Opportunity I L.P. 10% Owner |
2024-11-14 16:30:11 | 4,869,681 0 |
4,869,681 | Form 13G |
| 5 | Grant Julie Papanek Director |
2023-03-03 17:48:33 | 0 2,880,761 |
2,880,761 | Form 4 |
| 6 | Canaan XI L.P. Canaan Partners XI LLC 10% Owner |
2022-11-02 16:15:55 | 2,548,403 0 |
2,548,403 | Form 13D |
| 7 | Bender Jeremy CHIEF EXECUTIVE OFFICER |
2025-02-21 18:05:43 | 475,837 1,608,838 |
2,084,675 | Form 4 |
| 8 | Blackman Samuel C. HEAD OF R&D |
2024-12-12 16:06:23 | 1,034,015 1,000,000 |
2,034,015 | Form 4 |
| 9 | Atlas Venture Opportunity Fund I L.P. 10% Owner |
2022-07-06 16:42:35 | 991,396 0 |
991,396 | Form 4 |
| 10 | Merendino Lauren Chief Commercial Officer |
2025-02-28 19:50:59 | 666,256 0 |
666,256 | Form 3 |
| 11 | York Charles N II COO, CFO AND SECRETARY |
2025-02-21 18:10:03 | 444,763 0 |
444,763 | Form 4 |
| 12 | Dubow Adam GENERAL COUNSEL |
2025-02-21 18:08:31 | 168,470 0 |
168,470 | Form 4 |
| 13 | Ramasastry Saira Director |
2024-06-21 19:17:18 | 40,485 0 |
40,485 | Form 4 |
| 14 | Becker Daniel J. Director |
2023-06-26 19:15:02 | 37,500 0 |
37,500 | Form 4 |
| 15 | Dable Habib J Director |
2024-05-28 18:13:59 | 32,335 0 |
32,335 | Form 4 |
| 16 | Gladstone Michael Director |
2024-05-28 18:17:45 | 32,335 0 |
32,335 | Form 4 |
| 17 | Josey John A. Director |
2024-05-28 18:24:17 | 32,335 0 |
32,335 | Form 4 |
| 18 | Grossman William Director |
2024-05-28 18:44:36 | 32,335 0 |
32,335 | Form 4 |
| 19 | Nicholson Garry A Director |
2024-05-28 18:27:04 | 32,335 0 |
32,335 | Form 4 |
| 20 | Holles Natalie C. Director |
2024-05-28 18:21:04 | 32,335 0 |
32,335 | Form 4 |
| 21 | Garland J. Scott Director |
2024-05-28 18:48:07 | 32,335 0 |
32,335 | Form 4 |
| 22 | TAKEDA PHARMACEUTICAL CO LTD Takeda Pharmaceuticals U.S.A. Inc. MILLENNIUM PHARMACEUTICALS INC Takeda Ventures Inc. 10% Owner |
2023-02-03 17:06:04 | 0 0 |
0 | Form 13G |